More tools:Markets·Screener·Research·Chat

GRI Bio, Inc. Common Stock (GRI) Financial Statements

GRI Bio, Inc. Common Stock
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00XZQMLW5
XNAS · usd
1.95▼ 0.05 (-2.75%)
As of 2026-09-09
Valuation
Market Cap
Enterprise Value—
Trailing P/E—
Price / Sales—
EV / Revenue—
EV / EBITDA—
Financial Highlights
Revenue (TTM)—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin—
Net Debt—
Trading Information
Previous Close2.00
Day's Range1.90 – 2.67
52-Week Range0.18 – 6.70
Volume707.9K
Avg Volume603.4K
Share Statistics
Shares Outstanding
Employees5
ExchangeXNAS
Listed2023-04-24
Share count as of August 13, 2026
Loading Income Statement…
Key questions about GRI Bio, Inc. Common Stock (GRI)
What is GRI Bio, Inc. Common Stock's Market Cap?
GRI Bio, Inc. Common Stock's Market Cap is $4.3M, based on as-reported figures from SEC (XBRL) filings.
What is GRI Bio, Inc. Common Stock's Net Income (TTM)?
GRI Bio, Inc. Common Stock's Net Income (TTM) is -$9.7M, based on as-reported figures from SEC (XBRL) filings.
What is GRI Bio, Inc. Common Stock's EBITDA?
GRI Bio, Inc. Common Stock's EBITDA is -$9.7M, based on as-reported figures from SEC (XBRL) filings.
What is GRI Bio, Inc. Common Stock's Diluted EPS (TTM)?
GRI Bio, Inc. Common Stock's Diluted EPS (TTM) is -4.42, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Interest income
Net loss
Net loss per share of common stock, basic (in usd per share)—
Net loss per share of common stock, diluted (in usd per share)—